



Antiviral Therapy

Antiviral Therapy publishes original research on clinical development of antiviral agents and treatment of all viral diseases, including HIV. The journal also features review articles, editorials and commentaries on key studies.



Coming Soon: HIV and Women in Europe

A third of new HIV diagnoses in Europe are among women. The highly anticipated supplement *Exploring the story of women living with HIV in Europe* (Peter Reiss, Editor) tackles key issues, including:

- HIV diagnosis and testing
- Impact of HIV during childbearing years
- Long-term HIV management

Spotlight Issue: Viral Hepatitis in Latin America

Look out for our Spotlight issue on *Epidemiology, virology and pathogenesis of viral hepatitis with a focus on Latin America* (Mónica Viviana Alvarado-Mora, João Renato Rebelo Pinho and Stephen Locarnini, Editors).

Join Us on Twitter



International Medical Press is now on Twitter (@intmedpress). Follow us for updates on our latest published articles, highlights from our Editor's Choice and news on developments in antiviral research.

INTERNATIONAL
MEDICAL
PRESS

International Medical Press
36 St Mary-at-Hill
London EC3R 8DU
United Kingdom

tel: +44 (0)20 7398 0700
fax: +44 (0)20 7398 0701
e-mail: info@intmedpress.com
web: www.intmedpress.com

MOPL01 Monday Plenary Session

Plenary Session

Venue: Session Room 1**Time:** 08:50-10:30

Co-Chairs: Christopher Lee, Malaysia
 Elaine J. Abrams, United States
 Marina Mahatir, Malaysia

Grant Presentation: Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme

L. Bekker, South Africa; F. Barré-Sinoussi, France; L. Bekker, South Africa; F. Barré-Sinoussi, France

Award Presentation: Women, Girls and HIV Investigator's Award

F. Barré-Sinoussi, France; B. de Zaluendo, UNAIDS; F. Barré-Sinoussi, France; B. de Zaluendo, UNAIDS

Achieving Universal Access and Moving towards Elimination of New HIV Infections in Cambodia

M. Chhi Vun, Cambodia

Paediatrics: The Transition from Adolescence to Adulthood

L. Bekker, South Africa

HIV, Law and Stigma

A. Ahmed, United States

MOAC01 Recent Advances in HIV Prevention for Men Who Have Sex with Men

Oral Abstract Session

Venue: Session Room 1**Time:** 11:00-12:30

Co-Chairs: Carlos F. Caceres, Peru
 Iskandar Azwa, Malaysia

Differing identities, but comparable risks and HIV/STI burden, in married and unmarried men who have sex with men (MSM) in Mumbai

*K.H. Mayer, R. Gangakhedkar, M. Mimiaga, M. Sivasubramian, K. Biello, N. Abuelezam, S. Mane, V. Anand, S. Safren
 United States*

Recent experience of intimate partner violence reduces self-reported condom negotiation efficacy among gay and bisexual men

*C. Finneran, R. Stephenson
 United States*

Factors associated with acute HIV infection diagnosis in MSM, ANRS-Opportunity study

*K. Champenois, S. Le Vu, L. Cuzin, C. Semaille, Y. Yazdanpanah
 France*

Being unaware of being HIV-infected is associated with alcohol use disorders and high-risk sexual behaviours among men who have sex with men in Peru

*P. Vagenas, K. Ludford, P. Gonzales, J. Peinado, C. Cabezas, F. Gonzales, J. Lama, J. Sanchez, F. Altice
 United States*

The feasibility of implementing and evaluating combination HIV prevention interventions for high-risk populations in stigmatized settings: the case of men who have sex with men in Malawi

*S. Baral, A. Wirtz, V. Jumbo, S. Ketende, D. Kamba, C. Beyrer, E. Umar, S. Stromdahl, G. Trapence
 United States*

Moderated discussion

MOSY01 Treatment 2013 – Current Issues and Future Directions

Symposia Session

Venue: Session Room 2**Time:** 11:00-12:30

Co-Chairs: Tsitsi Mutasa-Apollo, Zimbabwe
 Gottfried Hirsenschall, WHO

Emerging evidence, new technologies and renewed political commitments set the scene for countries to dramatically expand their ARV programmes to achieve 2015 'universal access' targets. During the conference WHO will be launching its new consolidated guidelines on the use of ARVs for HIV treatment and prevention. The session will provide an update on recent developments in HIV treatment, including new scientific evidence, country responses and progress towards achieving global treatment targets. It will present the new WHO clinical recommendations for ARV use among adults, pregnant and breastfeeding women and children. The rationale for these recommendations will be discussed along with major research gaps and operational and programmatic implications for countries in implementing the recommendations. The session will also look into the future of HIV treatment, to consider priorities for optimizing ARV drugs, ART regimens and HIV diagnostics.

Introduction

T. Mutasa-Apollo, Zimbabwe; G. Hirsenschall (WHO), WHO; T. Mutasa-Apollo, Zimbabwe; G. Hirsenschall, WHO

Overview: new trends and developments in HIV treatment

T. Mutasa-Apollo, Zimbabwe

HIV treatment for adults and adolescents

S. Vella, Italy

Use of ARVs in pregnant women and children

E. Abrams, United States

Operational and programmatic considerations in scaling up ART

Y. Pillay, South Africa

ARVs and ART: looking to the future

S. Lewin, Australia

Moderated discussion

MOAD01 Connecting the Dots: Linkage and Retention

Oral Abstract Session

Venue: Session Room 3**Time:** 11:00-12:30

Co-Chairs: Josephine Birungi, Uganda
 Jeffrey Stringer, United States

Factors associated with client linkage to care following home-based HIV counseling and testing: a prospective cohort study in rural South Africa

*R. Naik, M. Fox, D. Jackson, T. Doherty, H. Tabana, F. Feeley
 South Africa*

Outcomes of newly diagnosed HIV-infected patients referred to care after provider initiated HIV counseling and testing in Uganda

*D. Kwarisiima, F.C. Semitala, N. Matsiko, J. Ngabirwe, J. Namusoby, C. Nawavvu, S. Muhumuza, M.R. Kamya
 Uganda*

Evaluation of a specialized psychosocial support intervention 'Teen Club' in improving retention among adolescents on antiretroviral treatment (ART) at a tertiary referral hospital in Malawi

*M. Agarwal, M. Van Lettow, J. Berman, C. Gondwe, E. Mwinjiwa, A. Chan
 Malawi*

Self-help groups of HIV patients may increase retention in care in northern Mozambique

*S. Pestilli, J. Llana-Garcia, E. Larsson, M. Hobbins, J. Ehmer, P. Wikman
 Mozambique*

Factors related to non-adherence to antiretroviral (ART) drugs among adult ART clients attending 18 facilities in Tanzania, Uganda and Zambia

*J.A. Denison, G. Kwesigabo, S. Tsui, O. Koole, J. Menten, M. Wang, D. Bangsberg, M. Mulenga, A. Auld, S. Agolory, Y.D. Mukadi, R. Colebunders, E. van Praag, K. Torpey, C. Geary, S. Williams, J. Kaplan, A. Zee, F. Wabwire-Mangen
 United Kingdom*

Moderated discussion

MOBS01 Immune Activation in HIV

Bridging Session

Venue: Session Room 4**Time:** 11:00-12:30**Co-Chairs:** Anne Hosmalin, France
Doug Nixon, United States

This session is directed towards basic scientists and clinicians interested in immune activation and its role in HIV infection, disease progression and inflammation. The presenters will offer a review of what is known as well as new data on T cell activation and inflammation and will address the following questions: Is inflammation a new surrogate for HIV progression? What is inflammation's role in progression, comorbidity and mortality? What are the best biomarkers for immune activation? What is the link between inflammation and T cell activation? What could cause immune activation? What have we learnt from immunomodulatory interventions and what is coming next? The presentations will be followed by a panel discussion.

Introduction**The role of immune activation in HIV pathogenesis***I.Sereti, United States***Novel immunomodulatory strategies for HIV infection***M.Paiardini, United States***The role of adaptive versus innate immune activation in non-AIDS morbidity***P.Hunt, United States***Questions and answers****MOME01 Managing Treatment Failure in Developed and Resource Limited Settings**

Meet the Experts

Venue: Session Room 3**Time:** 12:45-14:00**Seating limit:** 60**Chair:** Iskandar Azwa, Malaysia

Despite advances in the management of people living with HIV, and the remarkable improvements in morbidity and mortality, treatment failure still occurs. Identification and management of patients who have failed first-line therapy remains a challenge particularly in resource limited settings. This interactive session with HIV treatment experts from a developed country and a resource limited country setting will address the approach to evaluating and managing treatment failure in these two different settings. The use of laboratory tools to detect treatment failure, that is, viral load and CD4 and the role of ARV resistance testing will be discussed. Strategies to manage treatment failure in these two contrasting environments where the range of ARV drugs which are available for treatment switch is highly different will be highlighted.

Panellists:*J.Gallant, United States; M.Schecter, Brazil***Introduction***I.Azwa, Malaysia***Introduction****Case study 1****Case study 2****Case study 3****Case study 4****Closing remarks****MOSS01 Evidence-Based Drug Policies for an Effective HIV Response**

Special Session

Venue: Session Room 4**Time:** 13:00-14:00**Co-Chairs:** Chris Beyrer, United States

Michel Kazatchkine, UNAIDS

Why should physicians, researchers, service users, advocates and policy makers focusing on HIV learn and act for evidence-based narcotic drug policies? This question and others will be discussed by leading physicians, global health advocates and human rights defenders from Asia, Australia, Europe, and Latin America in an interactive panel.

Two of the Global Commissioners from the Global Commission on Drug Policy (GDPC) will take part in the session. The Commission unites prominent policy, intellectual and business leaders such as Kofi Annan from around the world to bring an informed, science-based discussion about humane and effective ways to reduce the harm caused by drugs to people and societies to the international community. The Commission's ground-breaking reports discuss how criminalization of drug use fuels the global HIV and hepatitis C pandemics.

This session is co-organized by the International AIDS Society, the Global Commission on Drug Policies and International Doctors for Healthier Drug Policies.

Introduction*C.Beyrer, United States; C.Beyrer, United States***HIV epidemic among people who use drugs***T.Kerr, Canada; T.Kerr, Canada***Human rights aspects of drug policy and how they relate to HIV***A.Jahangir, Pakistan***Civil society perspective***S.Phurailatpam, Thailand; S.Phurailatpam, Thailand***Malaysian experience***S.Kaur, Malaysia***Improving drug policies***M.Kazatchkine, UNAIDS; M.Kazatchkine, UNAIDS***Moderated discussion****Closing remarks***M.Kazatchkine, UNAIDS; M.Kazatchkine, UNAIDS***MOPDD01 Voluntary Medical Male Circumcision: Getting It Done**

Oral Poster Discussion Session

Venue: Mini Room 1**Time:** 13:00-14:00**Co-Chairs:** Karin Hatzold, United States
Thomas A. Odeny, Kenya**Implications of the rapid scale up and the expansion of VMMC in South Africa for quality of services***D.Rech, S.Frade, A.Spyrelis, L.Perry, C.Toledo, R.Fertziger, E.Njeuhmeli, J.Bertrand*
South Africa**The acceptability and safety of the Shang Ring for adult male circumcision in Rakai, Uganda***G.Kigozi, R.Musoke, S.Watya, F.Nalugoda, N.Kighoma, P.Ssebowo, D.Serwadda, F.Makumbi, F.Wabwire Mangen, N.Kiwanuka, N.Sewankambo, M.Wawer, R.H.Gray*
Uganda**The demand for voluntary male circumcision in Zambia: a sequential model of the decision process***P.Hewett, P.Todd, C.Mweemba, J.Price, B.Mensch*
Zambia**Loss to follow-up and adverse events following voluntary medical male circumcision in Nyanza Province, Kenya***J.Grund, J.B.Reed, Z.Mwandi, A.Ochieng, A.Howard, M.McNairy, Y.Liu, P.Cherutich, L.Kizito, M.Swaminathan, N.Bock*
United States**Behaviour change pathways to male circumcision: narrative interviews with 40 male circumcision (MC) clients in Zambia***J.Price, D.Mulenga, L.Phiri, K.Hatzold, N.Shillya, K.Bowa, P.Hewett*
Zambia**Moderated discussion**

MOPDC01 Testing: The First Step of the Cascade

Oral Poster Discussion Session

Venue: Mini Room 2**Time:** 13:00-14:00**Chair:** Andrew Grulich, Australia**Client-centered HIV testing and counseling as a strategy for scaling up access to HIV prevention and care services**

J. Mongare, F. Odhiambo, S. Ojoo, H. Ooko, M. Chege, D. Wandina, R. Redfield
 Kenya

A qualitative analysis of HIV testing patterns among black men who have sex with men in Atlanta, Georgia, USA

S. Hussen, R. Stephenson, C. del Rio, L. Wilton, J. Wallace, D. Wheeler, on behalf of HPTN 061
 United States

Gay male couples' attitude toward using an over-the-counter rapid HIV test in their home

J. Mitchell
 United States

Interventions to the improvement of access to HIV and TB testing and treatment for prisoners in Zambia

C. Mumba Jr., G. Malembeka
 Zambia

High uptake of mobile HIV testing in Bangkok metropolitan area, Thailand

A. Simaputtanasan, K. Phanjaroen, T. Pankam, S. Pattanachaiwit, R. Wongkanya, J. Barisri, A. Kanbomrung, S. Tongyoy, N. Phanuphak, S. Sirivichayakul, P. Phanuphak
 Thailand

Expanding access to non-medicalized community-based rapid testing to men who have sex with men: an urgent HIV prevention intervention (The ANRS-DRAG Study)

N. Lorente, M. Pr  au, C. Vernay-Vaisse, M. Mora, J. Blanche, J. Otis, A. Passeron, J.-M. Le Gall, P. Dhotte, M.P. Carrieri, M. Suzan-Monti, B. Spire, ANRS-DRAG study group
 France

Moderated discussion**MOPDB01 Growing Pains: Non-Infectious Conditions in Children**

Oral Poster Discussion Session

Venue: Mini Room 3**Time:** 13:00-14:00**Co-Chairs:** Stanley Read, Canada
Mark Cotton, South Africa**Cardiovascular abnormalities and carotid intima-media thickness (cIMT) among HIV-infected adolescents receiving long-term highly antiretroviral therapy in Thailand: a cross-sectional study with HIV-uninfected healthy controls**

V. Poornlek, P. Chanthong, K. Lapphra, S. Saihongthong, K. Choekphaibulkit
 Thailand

Prevalence of insulin resistance and metabolic syndrome among HIV-infected children receiving lopinavir/ritonavir-based antiretroviral therapy

N. Esmailzadeh, J. Wongsabut, T. Sahakitrungruang, P. Kosalaraksa, P. Suntarattiwong, T. Bunupuradah, T. Suwanlerk, T. Puthanakit, HIVNAT 152 study team
 Denmark

Longitudinal study of bone mineral density and vitamin D levels among perinatally HIV-infected Thai adolescents on long-term antiretroviral therapy

S. Tanchaweng, T. Puthanakit, R. Saksawad, C. Brukesawan, A. Maleesatharn, K. Choekphaibulkit
 Thailand

Prevalence of depression amongst HIV-infected adolescents in Malawi

M.H. Kim, A.C. Mazenga, A. Devendra, S. Ahmed, C. Sharp, J. Mhango, M. Bvumbwe, M. Machika, W. Kamuyango, A. Munthali, P.N. Kazembe
 Malawi

Moderated discussion**MOPDA01 Multi-Faceted Aspects of Acute HIV Infection**

Oral Poster Discussion Session

Venue: Mini Room 4**Time:** 13:00-14:00**Co-Chairs:** Christine Rouzioux, France
Anthony Kelleher, Australia**Introduction**

C. Rouzioux, France

Genetic diversity at endoplasmic reticulum aminopeptidases 2 (ERAP2) is coupled with resistance to HIV-1 infection

I. Saule, M. Biasin, M. Sironi, M. de Luca, F. la Rosa, R. Cagliani, S. lo Caputo, F. Mazzotta, M. Clerici
 Italy

Association of APOBEC3G genetic variants with HIV-1vif sequence variation and impact on HIV-1 pathogenesis

K. Reddy, M. Ooms, K. Mlisana, S. Abdool Karim, V. Simon, T. Ndung'u, CAPRISA Acute Infection Team
 South Africa

Viral protein U (Vpu) reduces innate sensing of human immunodeficiency virus type 1 (HIV-1)-infected T cells by plasmacytoid dendritic cells (pDCs) via a BST2-dependent process

M.G. Bego,  . B  rub  -C  t  , J. Mercier,  .A. Cohen
 Canada

ADCC responses arising during acute/early HIV infection do not prevent rapid disease progression

M.J. Ruiz, Y. Ghiglione, M.E. Soc  s, N. Laufer, P. Cahn, O. Sued, M.M. Gherardi, H. Salomon, A.M. Rodr  guez, G. Turk
 Argentina

T cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection

L. Weiss, M. Chevalier, L. Assoumou, C. Dider, P.-M. Girard, D. Costagliola, C. Rouzioux, ANRS116 SALTO Study Group
 France

Conclusion

A. Kelleher, Australia

Moderated discussion**MOAC02 Treatment as Prevention: A Work in Progress**

Oral Abstract Session

Venue: Session Room 1**Time:** 14:30-16:00**Co-Chairs:** Suwat Chariyalertsak, Thailand
Nagalingeswaran Kumarasamy, India**Early antiretroviral therapy, sexual behaviours and HIV-1 transmission risk: estimates from the Temprano-ANRS 12136 Randomized Controlled Trial, Abidjan, C  te d' Ivoire**

K. Jean, D. Gabillard, R. Moh, C. Danel, R. Fassassi, A. Desgr  es-du-Lo  , S. Eholi  , F. Lert, X. Anglaret, R. Dray-Spira
 France

Delay in antiretroviral therapy initiation is common among east African HIV-1-infected individuals in serodiscordant partnerships

A. Mujugira, C. Celum, K. Thomas, C. Farquhar, N. Mugo, E. Katabira, E. Bukusi, E. Tumwesigye, J. Baeten, Partners PrEP Study Team
 United States

The epidemiological impact and cost-effectiveness of expanded eligibility for and access to adult antiretroviral therapy in South Africa, Zambia, India and Vietnam: a twelve model analysis

J.W. Eaton, N.A. Menzies, J. Stover, V. Cambiano, L. Chindelevitch, A. Cori, J.A.C. Hontelez, S. Humair, C.C. Kerr, D.J. Klein, S. Mishra, K.M. Mitchell, B.E. Nichols, P. Vickerman, T. B  rnighausen, A. Bershteyn, D.E. Bloom, M.-C. Boily, S.T. Chang, T. Cohen, P.J. Dodd, C. Fraser, C. Gopalappa, J. Lundgren, N.K. Martin, E. Mountain, Q.D. Pham, M. Pickles, A. Phillips, L. Platt, C. Pretorius, H.J. Prudden, J.A. Salomon, D.A.M.C. van de Vijver, B.G. Wagner, R.G. White, D.P. Wilson, L. Zhang, J. Blandford, G. Meyer-Rath, M. Remme, F. Terris-Prestholt, P. Revill, N. Sangrujee, M. Doherty, P. Easterbrook, G. Hirschall, T.B. Hallett, HIV Modelling Consortium ART Eligibility Guidelines Working Group
 United Kingdom

Acceptability of early initiation of antiretrovirals for treatment as prevention among HIV-infected persons in Mochudi, Botswana

A. Logan, R. Plank, L. Bogart, K. Moloi, K. Maotonyane, H. Bussmann, L. Okui, F. Earls, M. Essex, S. Lockman Botswana

Modelling the expected impact of a treatment as prevention (TasP) implementation study on HIV incidence in Swaziland

G. Botha, V. Okello, C. Azih, A. Welte, A. End, F. Walsh, Y. Fleming, W. Delva South Africa

Moderated discussion

MOWS01 Controversies in the Management of HIV-Positive Adults: A Case-Based Approach

Professional Development Workshop

Venue: Session Room 2

Time: 14:30-16:00

Level: Advanced

Target audience: Pharmacist, Physician, Nurse practitioner

Seating limit: N/A

Facilitator: Roy Gulick, United States

This session will examine cases of HIV-positive adults and explore questions on when to start therapy, what to start, how and when to switch, and how to adjust treatment in the presence of comorbidity and coinfections. Participants will have an opportunity to discuss and identify their preferred choice of case management and the various options discussed by the international panel of experts.

When to start?

R. Gulick, United States

What to start?

A. Pozniak, United Kingdom

Switching for toxicity: how and when to switch?

L. Soto-Ramirez, Mexico

HIV drug resistance and treatment failure

S. Kiertburanakul, Thailand

Complications after antiretroviral therapy

W. Manosuthi, Thailand

MOSY03 Social and Structural Determinants of the HIV Epidemic in Eastern Europe and Central Asia

Symposia Session

Venue: Session Room 3

Time: 14:30-16:00

Co-Chairs: Sergii Dvoriak, Ukraine
Frederick Altice, United States

That health has many social determinants is well established, and a myriad of structural factors - social, cultural, political, economic, and environmental - are now known to impact population well-being. Public health practice has started exploring and responding to a range of health-related challenges from a structural paradigm, including individual and population vulnerability to HIV and AIDS. Recognising the inadequacy of public health responses that focus solely on individual behaviour change to improve population health outcomes, the aim of this session is to examine the social and structural factors related to the HIV epidemic in Eastern Europe and Central Asia, two regions currently most affected by the an injecting drug use epidemic.

Introduction

F. Altice, United States; F. Altice, United States

Social, structural and environmental determinants influencing scale-up of HIV prevention and treatment programmes for people who use drugs in Central Asia

A. Boltaev, United States

Social, economic, and structural determinants that impact HIV transmission amongst migrant workers in the region

B. Zhussupov, Kazakhstan

Social science of HIV and hepatitis C in Russia and southeastern Europe

S. Dvoriak, Ukraine

Drugs, HIV and the law in Eastern Europe and Central Asia

D. Ocheret, Ukraine

Economic and policy dimensions of HIV in Eastern Europe and Central Asia

D. Wilson, World Bank

Moderated discussion

MOAB01 Expanding ARV Options for Children: First Line and Beyond

Oral Abstract Session

Venue: Session Room 4

Time: 14:30-16:00

Co-Chairs: Diana M. Gibb, United Kingdom
Kamarul Azahar Mohd Razali, Malaysia

A randomized study comparing low dose versus standard dose lopinavir/ritonavir among HIV-infected children with virological suppression

T. Puthanakit, P. Suntarattiwong, P. Sangkla, P. Kosalaraksa, C. Ngampiyaskul, P. Srisamang, S. Kanjanavanit, J. Wongsawat, W. Petdachai, W. Chatchomchuan, N. Lertpienthum, J. Sophonphan, J. Ananworanich Thailand

Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to < 6 Years: week 48 analysis of the ARIEL trial

A. Violari, R. Bologna, N. Kumarasamy, J.H. Pilotto, A. Hendrickx, T.N. Kakuda, E. Lathouwers, M. Opsomer, T. Van de Castele, F.L. Tomaka South Africa

Safety and efficacy of maraviroc in CCR5-tropic HIV-1-infected children aged 2 to < 18 years

C. Giaquinto, L. Keet, C. Fortuny, A. Fang, M. Vourvahis, L. McFadyen, S.R. Valluri, G. Mukwaya, J. Heera Italy

Plasma efavirenz concentrations in HIV-infected children in Thailand: comparison between FDA and WHO 2010 dosing guidelines

N. Homkham, S. Urien, T.R. Cressey, C. Chanta, V. Sirisanthana, T. Narkbunnam, S. Krikajornkitti, N. Kamonpakorn, L. Ingsrisawang, J.M. Treluyer, G. Jourdain France

Long-term virological outcome in HIV-infected children on ART in the UK/ Ireland

T. Duong, A. Judd, K. Doerholt, H. Lyall, E. Menson, C. Foster, D. Shingadia, K. Butler, J. Collins, D. Dunn, D. Gibb, Collaborative HIV Paediatric Study (CHIPS) United Kingdom

Moderated discussion

MOAA01 What Drives Disease Progression and Limits CD4 Recovery?

Oral Abstract Session

Venue: Mini Room 2

Time: 14:30-16:00

Co-Chairs: Peter Hunt, United States
Irini Sereti, United States

Identification and characterization of CD4 T cells actively transcribing HIV RNA in peripheral blood

J. Casazza, A. Vostel, D. Ambrozak, B. Hill, E. Boritz, D. Douek, R. Koup United States

IP10 and sCD163 are biomarkers of CD4+ T cells decline and immune activation in HIV controllers patients

N. Noel, F. Boufassa, C. Lécuroux, A. Saez-Cirion, I. Girault, M. Conti, S. Hua, C. Bourgeois, C. Goujard, A. Venet, O. Lambotte France

HIV-1 infection reduces emigration of mature thymocytes from the human thymus by downregulation of the sphingosine-1-phosphate

receptor S1PR1

R.S. Resop, M. Douaisi, J. Craft, C. Uittenbogaart
 United States

T cell potential of CD34+ hematopoietic progenitors impact CD4+ T cell recovery under c-ART during HIV infection

I. Menkova, C. Benne, Y. Lévy, J.-D. Lelièvre
 France

Impaired isotype switching of IgG antibodies in HIV infection may be related to peripheral T-follicular helper cell dysfunction

L. Abdulai, S. Fernandez, J. Post, A. Lloyd, M. French
 Australia

Moderated discussion

MOWS02 Real-time Accessible Health Data: The Backbone of Programme Evaluation

Professional Development Workshop

Venue: Mini Room 4

Time: 14:30-17:30

Level: Foundation

Target audience: Educator/trainer, Policy / programme analyst, Researcher

Seating limit: 80

Co-Facilitators: Edris Mohammed Seid, Rwanda
 Sarawut Boonsuk, Thailand

The workshop will focus on the use of data to inform programme performance. Facilitators will discuss how data can be collected and used at multiple strata of healthcare delivery, from the individual facilities to the national level. The workshop will describe and discuss innovative methods for data collection and dissemination and share real life examples from HIV and other programmes. The potential impact of real time health data on clinical and prevention outcomes will be highlighted. Participants will discuss and debate potential standard and novel ways to address data collection and evaluation of some key HIV prevention and treatment issues, including scale-up of PMTCT services and evaluation of HIV treatment outcomes.

Introduction

E. Geng, United States; E. Geng, United States

A real-time electronic medical record to drive the quality improvement program of Haiti

B. Agins, United States

Thailand's experience with using programme data to improve PMTCT strategies and outcomes

S. Boonsuk, Thailand

The scale up and implementation of quality improvement in HIV treatment services in Rwanda, including the transition of these services from international partners (CDC and NGO) to MOH

E. Seid, Rwanda

Use of real-time bidirectional health information exchange and its positive impact on HIV-related outcomes

M. Magnus, United States

Case scenario and group work

Closing remarks

E. Geng, United States; E. Geng, United States

MOBS02 New Concepts in Using ARVs for Primary HIV Prevention

Bridging Session

Venue: Session Room 1

Time: 16:30-18:00

Chair: Linda-Gail Bekker, South Africa

Recent studies have demonstrated that oral and topical chemoprophylaxis can decrease HIV incidence, but many questions remain on how to best maximize efficacy. New directions for oral and topical chemoprophylaxis will need to be based on a better understanding of mucosal pharmacology and immunology. In addition, new formulations need to be designed that can be active in the setting of imperfect adherence, and may not need to be coitally dependent. The presentations in this symposium will summarize the newest concepts regarding next generation chemoprophylactic approaches, including the use of new drugs, new formulations, and new dosing strategies compared to the first generation approaches.

Introduction

Preclinical models to study new approaches to HIV prevention

G. Garcia-Lerma, United States

Pharmacology of antiretrovirals and HIV chemoprophylaxis

S. Kerr, Thailand

New drugs and delivery systems for chemoprophylaxis

R. Gulick, United States

Intermittent PrEP

J. Molina, France

Questions and answers

MOSY02 Host-Virus Interactions at the Mucosal Surface

Symposia Session

Venue: Session Room 2

Time: 16:30-18:00

Co-Chairs: Kristina Broliden, Sweden
 Barbara Shacklett, United States

This session will present an overview of recent state-of-the-art findings and data on mucosal barriers and tissues and their interactions with HIV. Mucosal tissues of genitourinary and reproductive tracts serve as major portals of entry for HIV transmission, while the intestinal mucosa corresponds to the major site of HIV replication. An understanding of the interactions at the mucosal surface is therefore critical for prevention strategies and for a better understanding of generalized immune activation. This symposium will provide an opportunity to learn about new research findings in each of these new areas including mechanisms of epithelial cell damage, microbial translocation, mucosal virome and microbiome, mucosal inflammation, gut innate cells, as well as the role of semen in inflammation and viral transmission. The implications for HIV transmission and pathogenesis will be discussed.

Introduction

The impact of SIV infection on gut innate lymphocyte populations and local gene expressions

R. Veazey, United States

The role of microbial communities and mucosal immunity in SIV disease progression

N. Klatt, United States

Genital tract inflammation, immune activation and HIV disease

J. Passmore, South Africa

Fluid and cellular host factors in the semen and their impact on inflammation and viral transmission

R. Le Grand, France

Questions and answers

MOAD02 PMTCT: Advancing the Cascade of Care

Oral Abstract Session

Venue: Session Room 3

Time: 16:30-18:00

Co-Chairs: Laura Guay, United States
 Angela Mushavi, Zimbabwe

Victor Valcour, United States

Effects of antenatal care-HIV service integration on utilization of prevention of mother to child transmission services and mother to child HIV transmission: results from a cluster-randomized controlled trial in Kenya

J.M. Turan, E.A. Bukusi, M. Onono, R.L. Steinfeld, S. Washington, S. Shade, C.R. Cohen
 United States

Towards getting more HIV-positive infants on lifesaving treatment: assessing turnaround times for early infant diagnosis in Lesotho

M. Gill, H.J. Hoffman, A. Isavwa, M. Mokone, M. Foso, J.T. Safrin, A. Tiam
 Lesotho

Preliminary findings of a routine PMTCT Option B+ program in a rural district in Malawi

R.M. Coulborn, L. Trivino Duran, C. Metcalf, Y. Namala, Z. Chirwa, M. Murowa, K. Mbewa, D. Garone
 Malawi

What happens to the babies? PMTCT outcomes among a community sample of HIV-exposed infants from Zimbabwe

F.M. Cowan, R. Buzdugan, S.I. McCoy, T.E. Martz, C. Watadzaushe, J. Dirawo, A. Mushavi, A. Mahomva, N.S. Padian
 United Kingdom

Food insecurity is a barrier to service uptake in the prevention of mother to child HIV transmission (PMTCT) cascade in Zimbabwe

S.I. McCoy, M.L. Ricculli, R. Buzdugan, A. Mushavi, A. Mahomva, C. Watadzaushe, J. Dirawo, F.M. Cowan, N.S. Padian
 United States

Moderated discussion

The workshop is a collaborative effort between community and clinicians seeking to understand long term impacts of ARV medication, HIV and co-morbidities on the lives of PLHIV. Living longer with HIV is more than viral suppression and attending to co-morbidities as a result of treatment. The workshop aims to illuminate current medical problems faced by PLHIV including toxicity relating to earlier therapy and lifestyle issues, with a view to increasing quality of life beyond the medical. The first part of the workshop will feature a debate: is earlier treatment better as it minimizes the impact of HIV on the brain, or worse because it exposes patients to more toxicity? A case-based discussion of prior solicited contexts and questions from the community will follow. Discussions about successful aging strategies for HIV will be encouraged.

Introduction

V.Valcour, United States; V.Valcour, United States

Keeping it upbeat: depression and psychiatric health

C.Bowonwatanuwong, Thailand

At the heart of longevity: cardiovascular health

P.Reiss, Netherlands

Liver health and aging

M.Klein, Canada

Moderated discussion

Closing remarks

S.Phurailatpam, Thailand; S.Phurailatpam, Thailand

MOSY04 It Is Not Just About the Men: Issues Related to Women Living with HIV

Symposia Session

Venue: Session Room 4

Time: 16:30-18:00

Co-Chairs: Catherine Hankins, Netherlands
 Kathleen Squires, United States

This session will provide a review of important management issues related to caring for women living with HIV. A panel of experts will discuss specific aspects of management that are unique to women living with HIV at various stages of their lifespan, including choosing the right ART and whether there is a women specific choice; analyzing pharmacokinetic issues related to dosing of ARV for treatment and prevention and important drug interactions, specifically with the oral contraceptive agents; addressing mental health issues in HIV-positive women; and finally discussing the impact of aging in women on certain comorbidities and ARV choices.

Introduction

Choosing ARVs for women: is there a preferred option?

M.Giles, Australia

Pharmacokinetic considerations for prevention and therapy of HIV in women

S.Bonora, Italy

Growing old with HIV: medical issues for the aging woman

M.Johnson, United Kingdom

Questions and answers

MOWS03 Living Longer with HIV: The Medical and Beyond

Professional Development Workshop

Venue: Mini Room 3

Time: 16:30-18:00

Level: Intermediate

Target audience: Community-based

Seating limit: 60

Co-Facilitators: Shiba Phurailatpam, Thailand